A phase 2 trial of radiation therapy with concurrent @entity1311 chemotherapy after surgery in XXXX with high-risk @entity1204 : a Korean Gynecologic Oncologic Group study.

@entity1 @entity137 @entity1311 @entity1204
PURPOSE: A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and @entity137 of concurrent chemoradiation with weekly @entity1311 in @entity1 with high-risk @entity1204 . METHODS AND MATERIALS: Pathologic requirements included @entity1204 stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. @entity1311 60 mg/m(2) was administered once weekly for 5 weeks during radiation therapy. RESULTS: Fifty-seven @entity1 were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 @entity137 were hematologic and usually self-limited. There was no life-threatening @entity137 . The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. CONCLUSIONS: Concurrent chemoradiation with weekly @entity1311 is well tolerated and seems to be effective for high-risk endometrioid @entity1204 . This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.
